Everything tagged "healthcare" across research, earnings, and macro.
10 articles
The short-report hit on Ensign is serious, but the selloff is running into a business that just posted record occupancy, 21.7% adjusted EPS growth, and higher full-year guidance. We see this as a test of whether allegations can overpower a long-running execution story, and right now execution still has the better numbers.
Ensign is turning skilled nursing into a repeatable growth machine, with double-digit revenue and EPS growth, record occupancy, and a balance sheet that still supports acquisitions. The stock looks like a quality compounder, but valuation keeps the stance at Buy on pullbacks.
Cooper Companies posted strong Q2 growth, with earnings and free cash flow improving despite a litigation charge. CooperVision remains the steady core, while CooperSurgical adds strategic upside after major recall claims were largely resolved.
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.
Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Abivax’s lead asset obefazimod delivered strong Phase 3 maintenance data in ulcerative colitis, shifting the story toward regulatory execution. The balance sheet is solid enough to fund the next catalysts, but the stock remains highly dependent on one program.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator